CO2021003412A2 - Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables - Google Patents
Nuevos derivados de tiazol y sus sales farmacéuticamente aceptablesInfo
- Publication number
- CO2021003412A2 CO2021003412A2 CONC2021/0003412A CO2021003412A CO2021003412A2 CO 2021003412 A2 CO2021003412 A2 CO 2021003412A2 CO 2021003412 A CO2021003412 A CO 2021003412A CO 2021003412 A2 CO2021003412 A2 CO 2021003412A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- thiazole derivatives
- new thiazole
- new
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
El presente invento proporciona un nuevo derivado de tiazol o una sal farmacéuticamente aceptable de éste y un método para prepararlo. El derivado de tiazol o una sal farmacéuticamente aceptable de éste, de acuerdo con el presente invento, tiene una actividad inhibidora selectiva contra la quinasa dependiente de ciclina (CDK) y, por lo tanto, puede usarse de manera útil como un agente preventivo o terapéutico para diversas enfermedades asociadas con la CDK.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180111001 | 2018-09-17 | ||
PCT/KR2019/011887 WO2020060112A1 (en) | 2018-09-17 | 2019-09-11 | Novel thiazole derivatives and pharmaceutically acceptable salts thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021003412A2 true CO2021003412A2 (es) | 2021-04-08 |
Family
ID=69887568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0003412A CO2021003412A2 (es) | 2018-09-17 | 2021-03-16 | Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables |
Country Status (19)
Country | Link |
---|---|
US (1) | US12110299B2 (es) |
EP (1) | EP3853225B1 (es) |
JP (1) | JP7235859B2 (es) |
KR (2) | KR102130253B1 (es) |
CN (1) | CN112739695A (es) |
AU (1) | AU2019344240B2 (es) |
BR (1) | BR112021004999A2 (es) |
CA (1) | CA3106855A1 (es) |
CL (1) | CL2021000594A1 (es) |
CO (1) | CO2021003412A2 (es) |
EA (1) | EA202190558A1 (es) |
IL (1) | IL280639B (es) |
MX (1) | MX2021002456A (es) |
PH (1) | PH12021550572A1 (es) |
SG (1) | SG11202100531RA (es) |
TW (1) | TW202023548A (es) |
UA (1) | UA125427C2 (es) |
WO (1) | WO2020060112A1 (es) |
ZA (1) | ZA202101652B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3853225B1 (en) | 2018-09-17 | 2023-11-29 | Yungjin Pharm. Co., Ltd. | N-(5-(3-(1-((thiazol-2-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide derivatives as cdk7 inhibitors for the treatment of cancer |
WO2021182914A1 (ko) * | 2020-03-13 | 2021-09-16 | 영진약품 주식회사 | 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4259341A (en) | 1977-06-01 | 1981-03-31 | Merck & Co., Inc. | Di- and tri-substituted thiazoles |
US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
EP1087951B9 (en) | 1998-06-18 | 2006-09-13 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
WO2000004926A2 (en) | 1998-07-22 | 2000-02-03 | Osprey Pharmaceuticals Limited | Conjugates for treating inflammatory disorders and associated tissue damage |
US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
DE60216097T2 (de) * | 2001-07-19 | 2007-06-28 | Pfizer Italia S.R.L. | Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel |
DK1700856T3 (en) | 2003-12-26 | 2015-12-14 | Kyowa Hakko Kirin Co Ltd | thiazole |
MX2007001846A (es) * | 2004-08-17 | 2007-03-28 | Hoffmann La Roche | Hidantoinas sustituidas. |
SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
US20090264415A2 (en) * | 2004-12-30 | 2009-10-22 | Steven De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment |
US20090105250A1 (en) | 2005-01-26 | 2009-04-23 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8183239B2 (en) | 2005-10-31 | 2012-05-22 | Janssen Pharmaceutica Nv | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor |
AU2007299870A1 (en) | 2006-09-22 | 2008-03-27 | Novartis Ag | Heterocyclic organic compounds |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
EP2155166A2 (en) | 2007-05-11 | 2010-02-24 | F. Hoffmann-Roche AG | Pharmaceutical compositions for poorly soluble drugs |
US20100249402A1 (en) | 2007-07-27 | 2010-09-30 | Dong Wha Pharmaceutical Co. Ltd. | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition for preventing or treating osteporosis comprising the same |
ES2331220B1 (es) | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
US20110263564A1 (en) * | 2008-10-29 | 2011-10-27 | Sirtris Pharmaceuticals, Inc. | Pyridine, bicyclic pyridine and related analogs as sirtuin modulators |
UA113383C2 (xx) | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів | |
US9221773B2 (en) | 2009-12-22 | 2015-12-29 | The Translational Genomics Research Institute | Benzamide derivatives |
WO2011084985A1 (en) * | 2010-01-07 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Cxcr3 receptor antagonists |
US8404859B2 (en) | 2011-03-16 | 2013-03-26 | Hoffmann-La Roche Inc. | Thiazole and thiophene compounds |
WO2012161879A1 (en) | 2011-05-23 | 2012-11-29 | Merck Patent Gmbh | Thiazole derivatives |
WO2013146754A1 (ja) | 2012-03-27 | 2013-10-03 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素5員環誘導体 |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
TW201443023A (zh) | 2013-01-18 | 2014-11-16 | 必治妥美雅史谷比公司 | 作爲rock抑制劑之酞□酮及異喹啉酮 |
WO2015058140A1 (en) | 2013-10-18 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
US10106526B2 (en) | 2014-04-04 | 2018-10-23 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
GB201417561D0 (en) | 2014-10-03 | 2014-11-19 | Redx Pharma Ltd | Compounds |
KR20160118417A (ko) | 2015-04-01 | 2016-10-12 | (주)황후연 | 살모사 뱀독 액상 혼합물의 아토피 화장품 및 연고의 원료 조성물 및 그 제조 방법 |
AU2016272900A1 (en) | 2015-06-04 | 2017-12-07 | Novartis Ag | Use of IL-1 beta binding antibodies to treat peripheral arterial disease |
MY190459A (en) * | 2015-06-04 | 2022-04-21 | Aurigene Discovery Tech Ltd | Substituted heterocyclyl derivatives as cdk inhibitors |
KR101802514B1 (ko) | 2016-12-09 | 2017-11-29 | 아주대학교산학협력단 | Nm를 포함하는 염증성 질환의 예방 또는 치료용 조성물 |
ES2676535B1 (es) | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
EP3853225B1 (en) | 2018-09-17 | 2023-11-29 | Yungjin Pharm. Co., Ltd. | N-(5-(3-(1-((thiazol-2-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide derivatives as cdk7 inhibitors for the treatment of cancer |
-
2019
- 2019-09-11 EP EP19862518.8A patent/EP3853225B1/en active Active
- 2019-09-11 JP JP2021514364A patent/JP7235859B2/ja active Active
- 2019-09-11 MX MX2021002456A patent/MX2021002456A/es unknown
- 2019-09-11 WO PCT/KR2019/011887 patent/WO2020060112A1/en active Application Filing
- 2019-09-11 CN CN201980060101.9A patent/CN112739695A/zh active Pending
- 2019-09-11 US US17/277,033 patent/US12110299B2/en active Active
- 2019-09-11 SG SG11202100531RA patent/SG11202100531RA/en unknown
- 2019-09-11 IL IL280639A patent/IL280639B/en unknown
- 2019-09-11 BR BR112021004999-1A patent/BR112021004999A2/pt not_active Application Discontinuation
- 2019-09-11 EA EA202190558A patent/EA202190558A1/ru unknown
- 2019-09-11 UA UAA202101314A patent/UA125427C2/uk unknown
- 2019-09-11 AU AU2019344240A patent/AU2019344240B2/en active Active
- 2019-09-11 KR KR1020190113157A patent/KR102130253B1/ko active IP Right Grant
- 2019-09-11 CA CA3106855A patent/CA3106855A1/en not_active Abandoned
- 2019-09-17 TW TW108133355A patent/TW202023548A/zh unknown
-
2020
- 2020-06-25 KR KR1020200078100A patent/KR20200078465A/ko active Application Filing
-
2021
- 2021-03-10 CL CL2021000594A patent/CL2021000594A1/es unknown
- 2021-03-11 ZA ZA2021/01652A patent/ZA202101652B/en unknown
- 2021-03-15 PH PH12021550572A patent/PH12021550572A1/en unknown
- 2021-03-16 CO CONC2021/0003412A patent/CO2021003412A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL280639B (en) | 2022-07-01 |
EP3853225A4 (en) | 2022-06-15 |
CA3106855A1 (en) | 2020-03-26 |
ZA202101652B (en) | 2022-07-27 |
US12110299B2 (en) | 2024-10-08 |
JP2021535924A (ja) | 2021-12-23 |
AU2019344240A1 (en) | 2021-02-25 |
PH12021550572A1 (en) | 2021-10-25 |
KR102130253B1 (ko) | 2020-07-03 |
AU2019344240B2 (en) | 2022-09-29 |
UA125427C2 (uk) | 2022-03-02 |
CN112739695A (zh) | 2021-04-30 |
EP3853225C0 (en) | 2023-11-29 |
EP3853225B1 (en) | 2023-11-29 |
EA202190558A1 (ru) | 2022-02-03 |
CL2021000594A1 (es) | 2021-12-03 |
IL280639A (en) | 2021-03-25 |
JP7235859B2 (ja) | 2023-03-08 |
US20210284658A1 (en) | 2021-09-16 |
BR112021004999A2 (pt) | 2021-06-08 |
EP3853225A1 (en) | 2021-07-28 |
WO2020060112A1 (en) | 2020-03-26 |
SG11202100531RA (en) | 2021-02-25 |
KR20200032002A (ko) | 2020-03-25 |
TW202023548A (zh) | 2020-07-01 |
MX2021002456A (es) | 2021-06-15 |
KR20200078465A (ko) | 2020-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019008487A2 (es) | Compuesto de quinazolina | |
CL2019003086A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
ECSP18093777A (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
MX2018013387A (es) | Inhibidores de la arginasa y sus aplicaciones terapeuticas. | |
ECSP20035222A (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa | |
CR20160537A (es) | Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico | |
CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
DOP2021000111A (es) | 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden | |
BR112018016729A2 (pt) | novo composto de tiofeno substituído nas posições 2,3,5, utilizado como inibidor de proteína quinase | |
CO2021003412A2 (es) | Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables | |
SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
SV2016005313A (es) | Derivados de carboxamida | |
DOP2012000058A (es) | Agente terapeutico para trastornos del estado de animo | |
CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
CO2020000374A2 (es) | Proceso mejorado para preparar derivados de aminopirimidina | |
CO2019012125A2 (es) | Inhibidores ip6k | |
UY36123A (es) | Derivados de carboxamida | |
CO2018001237A2 (es) | Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos | |
DOP2012000056A (es) | Agente terapeutico para trastornos de ansiedad | |
CL2017002229A1 (es) | Inhibidores de bace1. | |
CO2020000595A2 (es) | Intermedios novedosos útiles para la síntesis de derivados de aminopirimidina, proceso para prepararlos, y proceso para preparar derivados de aminopirimidina usando estos | |
CL2016002870A1 (es) | Derivados bicíclicos y composición farmacéutica que incluye los mismos | |
CL2020000175A1 (es) | Combinaciones farmacéuticas que comprenden anticuerpos contra bst1 y citadina. |